DE60131547D1 - Abführende zusammensetzungen - Google Patents

Abführende zusammensetzungen

Info

Publication number
DE60131547D1
DE60131547D1 DE60131547T DE60131547T DE60131547D1 DE 60131547 D1 DE60131547 D1 DE 60131547D1 DE 60131547 T DE60131547 T DE 60131547T DE 60131547 T DE60131547 T DE 60131547T DE 60131547 D1 DE60131547 D1 DE 60131547D1
Authority
DE
Germany
Prior art keywords
discharging
compositions
discharging compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60131547T
Other languages
English (en)
Other versions
DE60131547T2 (de
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60131547(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Application granted granted Critical
Publication of DE60131547D1 publication Critical patent/DE60131547D1/de
Publication of DE60131547T2 publication Critical patent/DE60131547T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
DE60131547T 2000-09-05 2001-09-04 Abführende zusammensetzungen Expired - Lifetime DE60131547T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US655760 2000-09-05
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition
PCT/JP2001/007628 WO2002020007A1 (en) 2000-09-05 2001-09-04 Cathartic composition

Publications (2)

Publication Number Publication Date
DE60131547D1 true DE60131547D1 (de) 2008-01-03
DE60131547T2 DE60131547T2 (de) 2008-10-23

Family

ID=24630250

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60131547T Expired - Lifetime DE60131547T2 (de) 2000-09-05 2001-09-04 Abführende zusammensetzungen
DE60142810T Expired - Lifetime DE60142810D1 (de) 2000-09-05 2001-09-04 Abführende Zusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60142810T Expired - Lifetime DE60142810D1 (de) 2000-09-05 2001-09-04 Abführende Zusammensetzungen

Country Status (25)

Country Link
US (7) US6414016B1 (de)
EP (2) EP1315485B1 (de)
JP (3) JP2004508327A (de)
KR (2) KR100901102B1 (de)
CN (1) CN100335049C (de)
AR (2) AR030609A1 (de)
AT (1) ATE476975T1 (de)
AU (2) AU8261501A (de)
BR (1) BRPI0114042B8 (de)
CA (1) CA2419741C (de)
CZ (1) CZ304740B6 (de)
DE (2) DE60131547T2 (de)
DK (2) DK1857105T3 (de)
ES (2) ES2296786T3 (de)
HU (1) HU229319B1 (de)
IL (2) IL154534A0 (de)
MX (1) MXPA03001959A (de)
NL (1) NL300757I1 (de)
NO (1) NO332701B1 (de)
NZ (1) NZ524401A (de)
PT (2) PT1315485E (de)
RU (1) RU2694361C3 (de)
TW (1) TWI305147B (de)
WO (1) WO2002020007A1 (de)
ZA (1) ZA200301673B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4332316B2 (ja) 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
CA2510051C (en) * 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
JP5147404B2 (ja) * 2005-01-27 2013-02-20 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
JP5213448B2 (ja) 2005-03-04 2013-06-19 スキャンポ・アーゲー 末梢血管疾患の処置のための方法および組成物
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
PL1871380T3 (pl) * 2005-04-12 2012-03-30 Sucampo Ag Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych
EP1984027B1 (de) 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmazeutische zusammensetzung mit einer bizyklischen verbindung sowie verfahren zur stabilisierung der bicyclischen verbindung
CN103755737A (zh) * 2006-02-07 2014-04-30 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
JP6113954B2 (ja) * 2008-10-31 2017-04-12 リピッド ファーマシューティカルズ イーエイチエフ． 医薬として使用するための脂肪酸
KR101766619B1 (ko) 2008-12-31 2017-08-08 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2010083597A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
US8940790B2 (en) * 2009-11-03 2015-01-27 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
CA2784933A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
EP2536705A4 (de) 2010-01-28 2013-08-07 Apotex Pharmachem Inc Polymorphe formen von lubiproston
KR102138390B1 (ko) 2012-08-21 2020-07-27 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 ｎｈｅ-매개된 역수송 저해를 위한 화합물 및 방법
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
EP2983667B1 (de) 2013-04-12 2019-03-20 Ardelyx, Inc. Nhe3-bindende verbindungen und verfahren zur phosphattransporthemmung
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US20170020890A1 (en) * 2015-06-19 2017-01-26 Sucampo Ag Pharmaceutical composition comprising fatty acid derivative
WO2018065826A1 (en) 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
AU2018206479B2 (en) 2017-01-09 2022-07-14 Ardelyx, Inc. Inhibitors of NHE-mediated antiport
WO2018193572A1 (ja) * 2017-04-20 2018-10-25 株式会社島津製作所 分光光度計
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (de) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
JP4372347B2 (ja) 1998-03-11 2009-11-25 あすか製薬株式会社 発泡性腸溶製剤
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
JP4332316B2 (ja) * 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
ES2279467T3 (es) * 2000-07-14 2007-08-16 Henkel Kommanditgesellschaft Auf Aktien Solido ahuecado compartimentado que contiene una porcion de detergente, producto de limpieza o aclarador.
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
EP1857105A2 (de) 2007-11-21
NO20030996L (no) 2003-05-02
RU2694361C9 (ru) 2019-12-25
CN1655776A (zh) 2005-08-17
NO20030996D0 (no) 2003-03-04
JP2009114217A (ja) 2009-05-28
US20030040528A1 (en) 2003-02-27
DE60142810D1 (de) 2010-09-23
AR100291A2 (es) 2016-09-28
KR100918223B1 (ko) 2009-09-21
DK1857105T3 (da) 2010-09-20
JP4684334B2 (ja) 2011-05-18
ZA200301673B (en) 2003-11-26
HUP0302422A2 (hu) 2003-10-28
NO332701B1 (no) 2012-12-10
JP2004508327A (ja) 2004-03-18
RU2694361C2 (ru) 2019-07-12
DE60131547T2 (de) 2008-10-23
CZ304740B6 (cs) 2014-09-17
HUP0302422A3 (en) 2005-02-28
CN100335049C (zh) 2007-09-05
ES2296786T3 (es) 2008-05-01
IL154534A (en) 2010-04-29
BRPI0114042B8 (pt) 2021-05-25
ES2347697T3 (es) 2010-11-03
US20140235665A1 (en) 2014-08-21
US8071613B2 (en) 2011-12-06
EP1315485A1 (de) 2003-06-04
JP2009286806A (ja) 2009-12-10
US6414016B1 (en) 2002-07-02
PT1857105E (pt) 2010-10-08
US8114890B1 (en) 2012-02-14
AR030609A1 (es) 2003-08-27
CA2419741C (en) 2010-11-30
PT1315485E (pt) 2008-01-23
IL154534A0 (en) 2003-09-17
US8748454B2 (en) 2014-06-10
MXPA03001959A (es) 2003-06-24
KR20080091278A (ko) 2008-10-09
EP1315485B1 (de) 2007-11-21
AU8261501A (en) 2002-03-22
US20050222195A1 (en) 2005-10-06
US6610732B2 (en) 2003-08-26
NL300757I2 (de) 2015-12-29
ATE476975T1 (de) 2010-08-15
US20120237598A1 (en) 2012-09-20
BR0114042A (pt) 2003-07-22
KR100901102B1 (ko) 2009-06-08
TWI305147B (en) 2009-01-11
NL300757I1 (de) 2015-12-29
AU2001282615B2 (en) 2006-06-22
DK1315485T3 (da) 2008-03-03
EP1857105B1 (de) 2010-08-11
EP1857105A3 (de) 2008-03-05
BRPI0114042B1 (pt) 2016-11-08
HU229319B1 (en) 2013-10-28
WO2002020007A1 (en) 2002-03-14
US20120022152A1 (en) 2012-01-26
RU2694361C3 (ru) 2020-07-20
KR20030029919A (ko) 2003-04-16
NZ524401A (en) 2004-08-27
CA2419741A1 (en) 2002-03-14
US20030216465A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
DE60131547D1 (de) Abführende zusammensetzungen
ATE303787T1 (de) Schergelzusammensetzungen
AR028197A1 (es) Composiciones antitranspirantes
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
IS2932B (is) Fúlvestrant samsetning
AR028320A1 (es) Nuevas composiciones de antihelminticos
ITMI20010748A0 (it) Composizioni farmaceutiche
AR023440A1 (es) Composiciones antitranspirantes
ID29785A (id) Komposisi-komposisi sampo
DE60007731D1 (de) Schweisshemmende zusammensetzungen
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
NO20026123L (no) Farmasöytiske sammensetninger
DE60139499D1 (de) Reinigungsmittelzusammensetzungen
ATE305502T1 (de) Waschmittelzusammensetzungen
DE60139896D1 (de) Ldenden zusammensetzungen
DE60116858D1 (de) Zusammensetzung
NO20031095L (no) Farmasoytiske sammensetninger
NO20023976L (no) Endoparasittiske sammensetninger
ATE264905T1 (de) Waschmittelzusammensetzungen
DE60104652D1 (de) Waschmittelzusammensetzungen
MA25655A1 (fr) Compositions detergentes
ATE340842T1 (de) Waschmittelzusammensetzungen
DE60107312D1 (de) Feste Zusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition